Novartis Reports ORION-4 Cardiovascular Outcomes Data for Leqvio
Biotechnology Media Insights
Editorial Team · July 22, 2024
Novartis presents ORION-4 cardiovascular outcomes trial data showing Leqvio significantly reduces major adverse cardiovascular events in patients with established CVD.
Novartis today presented data from the ORION-4 cardiovascular outcomes trial evaluating Leqvio (inclisiran) in patients with established cardiovascular disease. The trial demonstrated a significant reduction in major adverse cardiovascular events with Leqvio compared to placebo, confirming that LDL cholesterol reduction with inclisiran translates into cardiovascular event reduction.
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.